Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 7/20 | 0.58 |
| ▸ | GRIN2A | Q12879 | 7/20 | 0.58 |
| ▸ | GRIN2D | O15399 | 6/20 | 0.58 |
| ▸ | GRIN3B | O60391 | 6/20 | 0.58 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.58 |
| ▸ | GRIN2C | Q14957 | 6/20 | 0.58 |
| ▸ | GRIN3A | Q8TCU5 | 6/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.58 |
| ▸ | ESR1 | P03372 | 1/20 | 0.58 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.58 |
| ▸ | MTOR | P42345 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL658298 | 0.86 | LMNA (0.39) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL658479 | 0.76 | GRIN1 (0.62) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL12959066 | 0.75 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL2689 | 0.75 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL13198606 | 0.75 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL23327176 | 0.75 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL8126868 | 0.75 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL2688 | 0.75 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL5608589 | 0.75 | GRIN1 (0.90) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL5606188 | 0.75 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9453017-B2 | Antiviral therapies with phospholipase D inhibitors | VANDERBILT UNIVERSITY (US) | 2016-09-27 | — | — | US | claimed |
| EP-2331495-B1 | PROCESS FOR MANUFACTURING ADAMANTANE DERIVATIVES WITH HIGH YIELD | MERZ PHARMA GMBH & CO KGAA (DE) | 2016-01-27 | — | — | EP | claimed |
| US-20120157537-A1 | NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau | IQBAL KHALID (US) | 2012-06-21 | — | — | US | claimed |
| US-20110263900-A1 | PROCESS FOR MANUFACTURING ADAMANTANE DERVATIVES WITH HIGH YIELD | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-10-27 | — | — | US | claimed |
| EP-2331495-A1 | PROCESS FOR MANUFACTURING ADAMANTANE DERIVATIVES WITH HIGH YIELD | Merz Pharma GmbH & Co. KGaA (DE) | 2011-06-15 | — | — | EP | claimed |
| WO-2010015415-A1 | PROCESS FOR MANUFACTURING ADAMANTANE DERIVATIVES WITH HIGH YIELD | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-02-11 | — | — | WO | claimed |
| US-20090124659-A1 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase and inhibitors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-05-14 | — | — | US | claimed |
| US-20090005459-A1 | NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau | IQBAL KHALID | 2009-01-01 | — | — | US | claimed |
| EP-1682109-B1 | THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC AS PEPTIDES IN AMYLOIDOPATHIES | MERZ PHARMA GMBH & CO KGAA (DE) | 2008-10-15 | — | — | EP | claimed |
| EP-1838297-A1 | 1-AMINOCYCLOHEXANE-DERIVATIVES FOR THE TREATMENT OF MULTIPLE SCLEROSIS EMOTIONAL LABILITY AND PSEUDOBULBAR AFFECT | Merz Pharma GmbH & Co. KGaA (DE) | 2007-10-03 | — | — | EP | claimed |
| US-20060205822-A1 | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect | FOREST LABORATORIES, INC. (US) | 2006-09-14 | — | — | US | claimed |
| EP-1682109-A1 | THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC AS PEPTIDES IN AMYLOIDOPATHIES | Merz Pharma GmbH & Co. KGaA (DE) | 2006-07-26 | — | — | EP | claimed |
| WO-2006069294-A1 | 1-AMINOCYCLOHEXANE-DERIVATIVES FOR THE TREATMENT OF MULTIPLE SCLEROSIS EMOTIONAL LABILITY AND PSEUDOBULBAR AFFECT | MERZ PHARMA GMBH & CO. KGAA (DE) | 2006-06-29 | — | — | WO | claimed |
| WO-2005079779-A1 | THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC Aß PEPTIDES IN AMYLOIDOPATHIES | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-09-01 | — | — | WO | claimed |
| EP-1556019-A2 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | Merz Pharma GmbH & Co. KGaA (DE) | 2005-07-27 | — | — | EP | claimed |
| US-20050113458-A1 | delivering to said cell an 1-aminocyclohexane derivative; for decreasing the level of at least one amyloid peptide produced by a mammalian cell that expresses amyloid precursor protein | FOREST LABORATORIES, INC. (US) | 2005-05-26 | — | — | US | claimed |
| WO-2004037234-A2 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2004-05-06 | — | — | WO | claimed |
| US-20040087658-A1 | Synergistic mixture; Alzheimer's disease therapy | MERZ PHARMA GMBH & CO. KGAA (DE) | 2004-05-06 | — | — | US | claimed |
| US-20040019118-A1 | NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau | IQBAL KHALID (US) | 2004-01-29 | — | — | US | claimed |
| US-20210169864-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | MERZ PHARMA GMBH & CO KGAA (DE) | 2021-06-10 | — | — | US | disclosed |
| US-20170319611-A1 | METHODS AND COMPOSITIONS COMPRISING AKT INHIBITORS AND/OR PHOSPHOLIPASE D INHIBITORS | UNIV VANDERBILT (US) | 2017-11-09 | — | — | US | disclosed |
| US-9453017-B2 | Antiviral therapies with phospholipase D inhibitors | VANDERBILT UNIVERSITY (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160136144-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2016-05-19 | — | — | US | disclosed |
| US-20160030391-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-02-04 | — | — | US | disclosed |
| EP-2331495-B1 | PROCESS FOR MANUFACTURING ADAMANTANE DERIVATIVES WITH HIGH YIELD | MERZ PHARMA GMBH & CO KGAA (DE) | 2016-01-27 | — | — | EP | disclosed |
| EP-2968257-A1 | METHODS AND COMPOSITONS FOR IMPROVING COGNITIVE FUNCTION | The Johns Hopkins University (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2931277-A1 | METHODS AND COMPOSITIONS COMPRISING AKT INHIBITORS AND/OR PHOSPHOLIPASE D INHIBITORS | Vanderbilt University (US) | 2015-10-21 | — | — | EP | disclosed |
| US-20150025041-A1 | ANTIVIRAL THERAPIES WITH PHOSPHOLIPASE D INHIBITORS | VANDERBILT UNIVERSITY (US) | 2015-01-22 | — | — | US | disclosed |
| US-20140378524-A1 | METHODS AND COMPOSITIONS COMPRISING AKT INHIBITORS AND/OR PHOSPHOLIPASE D INHIBITORS | VANDERBILT UNIVERSITY | 2014-12-25 | — | — | US | disclosed |
| US-20140371260-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | MERZ PHARMA GMBH & CO. KGAA (GE) | 2014-12-18 | — | — | US | disclosed |
| US-20140350114-A1 | COMPOSITIONS COMPRISING CYCLOHEXYLAMINES AND AMINOADAMANTANES | MERZ PHARMA GMBH & CO KGAA (DE) | 2014-11-27 | — | — | US | disclosed |
| US-20140348932-A1 | IMMEDIATE RELEASE FORMULATIONS OF 1-AMINOCYCLOHEXANE COMPOUNDS, MEMANTINE AND NERAMEXANE | FOREST LAB HOLDINGS LTD (BM) | 2014-11-27 | — | — | US | disclosed |
| WO-2014153180-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GALLAGHER MICHELA (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014144546-A1 | METHODS AND COMPOSITONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-09-18 | — | — | WO | disclosed |
| US-8834924-B2 | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2014-09-16 | — | — | US | disclosed |
| EP-2760447-A1 | ANTIVIRAL THERAPIES WITH PHOSPHOLIPASE D INHIBITORS | Vanderbilt University (US) | 2014-08-06 | — | — | EP | disclosed |
| US-8796491-B2 | Process for manufacturing adamantane derivatives with high yield | MERZ PHARMA GMBH & CO. KGAA (DE) | 2014-08-05 | — | — | US | disclosed |
| WO-2014093557-A1 | METHODS AND COMPOSITIONS COMPRISING AKT INHIBITORS AND/OR PHOSPHOLIPASE D INHIBITORS | VANDERBILT UNIVERSITY (US) | 2014-06-19 | — | — | WO | disclosed |
| EP-2601937-A1 | Drinkable immediate release tablet made with direct compression of memantine or neramexane | Merz Pharma GmbH & Co. KGaA (DE) | 2013-06-12 | — | — | EP | disclosed |
| WO-2013049773-A1 | ANTIVIRAL THERAPIES WITH PHOSPHOLIPASE D INHIBITORS | VANDERBILT UNIVERSITY (US) | 2013-04-04 | — | — | WO | disclosed |
| US-20120238631-A1 | COMPOSITIONS COMPRISING CYCLOHEXYLAMINES AND AMINOADAMANTANES | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-09-20 | — | — | US | disclosed |
| US-20120157537-A1 | NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau | IQBAL KHALID (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120046302-A1 | METHODS OF TREATING CNS DISORDERS | PAPADAKIS KELLY (US) | 2012-02-23 | — | — | US | disclosed |
| EP-2397122-A2 | Formulations of neramexane dosage forms | Merz Pharma GmbH & Co. KGaA (DE) | 2011-12-21 | — | — | EP | disclosed |
| US-20110263900-A1 | PROCESS FOR MANUFACTURING ADAMANTANE DERVATIVES WITH HIGH YIELD | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110236439-A1 | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-09-29 | — | — | US | disclosed |
| US-20110201665-A1 | Compositions, Methods, and Kits for Treating Influenza Viral Infections | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2011-08-18 | — | — | US | disclosed |
| EP-2331495-A1 | PROCESS FOR MANUFACTURING ADAMANTANE DERIVATIVES WITH HIGH YIELD | Merz Pharma GmbH & Co. KGaA (DE) | 2011-06-15 | — | — | EP | disclosed |
| EP-2289489-A2 | Compositions comprising cyclohexylamines and aminoadamantanes | Merz Pharma GmbH & Co. KGaA (DE) | 2011-03-02 | — | — | EP | disclosed |
| US-20110028510-A1 | Compositions, Methods, and Kits for Treating Influenza Viral Infections | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2011-02-03 | — | — | US | disclosed |
| WO-2011001258-A1 | COMPOSITIONS, METHODS, AND KITS FOR TREATING VIRAL AND BACTERIAL INFECTIONS BY TOCOTRIENOLS, TOCOMONOENOLS, TOCODIENOLS, TOCOPHEROLS, AND THEIR DERIVATES | EVITA LIFE SCIENCE PTE. LTD (SG) | 2011-01-06 | — | — | WO | disclosed |
| EP-2260839-A2 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors | Merz Pharma GmbH & Co. KGaA (DE) | 2010-12-15 | — | — | EP | disclosed |
| EP-2260844-A1 | Combination of an NMDA Receptor Antagonist and a Selective Serotonin Reuptake Inhibitor for the Treatment of Depression and other Mood Disorders | Merz Pharma GmbH & Co. KGaA (DE) | 2010-12-15 | — | — | EP | disclosed |
| US-20100227852-A1 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-09-09 | — | — | US | disclosed |
| WO-2010095041-A2 | COMPOSITIONS, METHODS, AND KITS FOR TREATING INFLUENZA VIRAL INFECTIONS | EXCRX (SINGAPORE) PTE.LTD. (SG) | 2010-08-26 | — | — | WO | disclosed |
| US-20100076073-A1 | Combination of an NMDA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-03-25 | — | — | US | disclosed |
| WO-2010015415-A1 | PROCESS FOR MANUFACTURING ADAMANTANE DERIVATIVES WITH HIGH YIELD | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-02-11 | — | — | WO | disclosed |
| US-20100035995-A1 | Compositions comprising Cyclohexylamines and Aminoadamantanes | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-02-11 | — | — | US | disclosed |
| US-20100028427-A1 | IMMEDIATE RELEASE FORMULATIONS OF 1-AMINOCYCLOHEXANE COMPOUNDS, MEMANTINE AND NERAMEXANE | FOREST LABORATORIES, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| EP-2138173-A1 | Pharmaceutical compositions comprising aminoadamantane derivatives | Merz Pharma GmbH & Co.KGaA (DE) | 2009-12-30 | — | — | EP | disclosed |
| US-20090275597-A1 | METHODS OF TREATING CNS DISORDERS | FOREST LABORATORIES HOLDINGS LIMITED (BE) | 2009-11-05 | — | — | US | disclosed |
| EP-2111858-A1 | Novel treatment for alzheimer's disease | EPFL Ecole Polytechnique Fédérale de Lausanne (CH) | 2009-10-28 | — | — | EP | disclosed |
| US-20090124659-A1 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase and inhibitors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-05-14 | — | — | US | disclosed |
| US-20090081259-A1 | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-03-26 | — | — | US | disclosed |
| US-20090005459-A1 | NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau | IQBAL KHALID | 2009-01-01 | — | — | US | disclosed |
| EP-1682109-B1 | THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC AS PEPTIDES IN AMYLOIDOPATHIES | MERZ PHARMA GMBH & CO KGAA (DE) | 2008-10-15 | — | — | EP | disclosed |
| US-20070270500-A1 | Compositions Comprising Cyclohexylamines and Aminoadamantanes | DEDHIYA MAHENDRA G | 2007-11-22 | — | — | US | disclosed |
| EP-1603548-A4 | METHOD AND COMPOSITION FOR TREATING NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS INC (US) | 2007-10-10 | — | — | EP | disclosed |
| EP-1765287-A2 | IMMEDIATE RELEASE FORMULATIONS OF MEMANTINE ORAL DOSAGE FORMS | Merz Pharma GmbH & Co. KGaA (DE) | 2007-03-28 | — | — | EP | disclosed |
| US-20060270742-A1 | Compositions and methods for the treatment of neurodegenerative diseases | COMBINATORX, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2006119295-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | COMBINATORX, INCORPORATED (US) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006096194-A2 | DRINKABLE IMMEDIATE RELEASE TABLET MADE WITH DIRECT COMPRESSION OF MEMANTINE OR NERAMEXANE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2006-09-14 | — | — | WO | disclosed |
| US-20060205822-A1 | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect | FOREST LABORATORIES, INC. (US) | 2006-09-14 | — | — | US | disclosed |
| US-20060198884-A1 | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane | FOREST LABORATORIES, INC. (US) | 2006-09-07 | — | — | US | disclosed |
| EP-1684715-A2 | COMPOSITIONS COMPRISING CYCLOHEXYLAMINES AND AMINOADAMANTANES | Merz Pharma GmbH & Co. KGaA (DE) | 2006-08-02 | — | — | EP | disclosed |
| US-20060002999-A1 | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane | FOREST LABORATORIES, INC. (US) | 2006-01-05 | — | — | US | disclosed |
| US-20050288375-A1 | Method and composition for treating neurodegenerative disorders | MYRIAD GENETICS, INCORPORATED (US) | 2005-12-29 | — | — | US | disclosed |
| EP-1603548-A2 | METHOD AND COMPOSITION FOR TREATING NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS, INC. (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20050203191-A1 | 1-Aminocyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease | FOREST LABORATORIES, INC. (US) | 2005-09-15 | — | — | US | disclosed |
| US-20050113458-A1 | delivering to said cell an 1-aminocyclohexane derivative; for decreasing the level of at least one amyloid peptide produced by a mammalian cell that expresses amyloid precursor protein | FOREST LABORATORIES, INC. (US) | 2005-05-26 | — | — | US | disclosed |
| WO-2005044228-A2 | COMPOSITIONS COMPRISING CYCLOHEXYLAMINES AND AMINOADAMANTANES | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-05-19 | — | — | WO | disclosed |
| EP-1523309-A2 | NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN TAU | Iqbal, Khalid (US) | 2005-04-20 | — | — | EP | disclosed |
| US-20050014743-A1 | Combination of an NMDA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders | FOREST LABORATORIES, INC. (US) | 2005-01-20 | — | — | US | disclosed |
| WO-2004071431-A2 | METHOD AND COMPOSITION FOR TREATING NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS, INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| US-20040087658-A1 | Synergistic mixture; Alzheimer's disease therapy | MERZ PHARMA GMBH & CO. KGAA (DE) | 2004-05-06 | — | — | US | disclosed |
| WO-2004009062-A2 | NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau | IQBAL KHALID (US) | 2004-01-29 | — | — | WO | disclosed |
| US-20040019118-A1 | NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau | IQBAL KHALID (US) | 2004-01-29 | — | — | US | disclosed |
| EP-0392059-B1 | USE OF ADAMANTANE DERIVATIVES IN THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA | Merz & Co. GmbH & Co. (DE) | 1993-09-15 | — | — | EP | disclosed |
| US-5061703-A | ALZHEIMER*S DISEASE | MERZ + CO. GMBH & CO. (DE) | 1991-10-29 | — | — | US | disclosed |
| EP-0392059-A1 | Use of adamantane derivatives in the prevention and treatment of cerebral ischemia | Merz & Co. GmbH & Co. (DE) | 1990-10-17 | — | — | EP | disclosed |
| EP-0392059-A1 | Use of adamantane derivatives in the prevention and treatment of cerebral ischemia | Merz & Co. GmbH & Co. (DE) | 1990-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (35 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140348932-A1 | IMMEDIATE RELEASE FORMULATIONS OF 1-AMINOCYCLOHEXANE COMPOUNDS, MEMANTINE AND NERAMEXANE | ADORA1, ADORA2A, SARAF | GRIN1 58/4885GRIN2A 17/4885GRIN2D 8/4885 |
| US-20120157537-A1 | NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau | GRIN1, GRIN2A, MAPT | GRIN1 1/4885GRIN2A 2/4885GRIN2D 12/4885 |
| US-20060002999-A1 | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane | ADORA1, ADORA2A, SARAF | GRIN1 58/4885GRIN2A 17/4885GRIN2D 8/4885 |
| US-20140371260-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | ACHE, BACE1, CHRNE | GRIN1 24/4885GRIN2A 37/4885GRIN2D 159/4885 |
| US-20120238631-A1 | COMPOSITIONS COMPRISING CYCLOHEXYLAMINES AND AMINOADAMANTANES | AAAS, SI, ACMSD | GRIN1 4139/4885GRIN2A 3295/4885GRIN2D 3759/4885 |
| US-20050203191-A1 | 1-Aminocyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease | ACHE, PNMT, APH1A | GRIN1 72/4885GRIN2A 53/4885GRIN2D 79/4885 |
| US-20100227852-A1 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors | ACHE, BACE1, CHRNE | GRIN1 24/4885GRIN2A 37/4885GRIN2D 159/4885 |
| US-20160136144-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | ACHE, PSEN1, BCHE | GRIN1 34/4885GRIN2A 40/4885GRIN2D 162/4885 |
| US-20210169864-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | ACHE, PSEN1, BCHE | GRIN1 34/4885GRIN2A 40/4885GRIN2D 162/4885 |
| US-20060270742-A1 | Compositions and methods for the treatment of neurodegenerative diseases | PSEN2, PSEN1, HTT | GRIN1 221/4885GRIN2A 80/4885GRIN2D 320/4885 |
| US-20140378524-A1 | METHODS AND COMPOSITIONS COMPRISING AKT INHIBITORS AND/OR PHOSPHOLIPASE D INHIBITORS | PLD1, PLD2, PIK3CD | GRIN1 3083/4885GRIN2A 3663/4885GRIN2D 2147/4885 |
| US-20100076073-A1 | Combination of an NMDA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders | GRIN2A, GRIN2B, GRIN3B | GRIN1 5/4885GRIN2A 1/4885GRIN2D 10/4885 |
| US-20100028427-A1 | IMMEDIATE RELEASE FORMULATIONS OF 1-AMINOCYCLOHEXANE COMPOUNDS, MEMANTINE AND NERAMEXANE | ADORA1, ADORA2A, SARAF | GRIN1 58/4885GRIN2A 17/4885GRIN2D 8/4885 |
| US-20090005459-A1 | NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau | GRIN1, GRIN2A, MAPT | GRIN1 1/4885GRIN2A 2/4885GRIN2D 12/4885 |
| US-20040019118-A1 | NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau | GRIN2A, GRIN1, MAPT | GRIN1 2/4885GRIN2A 1/4885GRIN2D 14/4885 |
| US-20110201665-A1 | Compositions, Methods, and Kits for Treating Influenza Viral Infections | IL5, CCL5, CCL11 | GRIN1 4826/4885GRIN2A 4854/4885GRIN2D 4867/4885 |
| US-20110028510-A1 | Compositions, Methods, and Kits for Treating Influenza Viral Infections | IL5, CCL5, CCL11 | GRIN1 4826/4885GRIN2A 4854/4885GRIN2D 4867/4885 |
| US-20090124659-A1 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase and inhibitors | ACHE, BACE1, BCHE | GRIN1 26/4885GRIN2A 36/4885GRIN2D 140/4885 |
| US-20160030391-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2A, GRIN2D, GRM2 | GRIN1 14/4885GRIN2A 1/4885GRIN2D 2/4885 |
| US-20100035995-A1 | Compositions comprising Cyclohexylamines and Aminoadamantanes | AAAS, SI, ACMSD | GRIN1 4139/4885GRIN2A 3295/4885GRIN2D 3759/4885 |
| US-20090275597-A1 | METHODS OF TREATING CNS DISORDERS | GRIN3A, GRIN2A, GRIN2B | GRIN1 8/4885GRIN2A 2/4885GRIN2D 14/4885 |
| US-20050113458-A1 | delivering to said cell an 1-aminocyclohexane derivative; for decreasing the level of at least one amyloid peptide produced by a mammalian cell that expresses amyloid precursor protein | APP, BACE1, PSEN1 | GRIN1 14/4885GRIN2A 13/4885GRIN2D 68/4885 |
| US-20110263900-A1 | PROCESS FOR MANUFACTURING ADAMANTANE DERVATIVES WITH HIGH YIELD | BACE1, BACE2, APP | GRIN1 958/4885GRIN2A 870/4885GRIN2D 1299/4885 |
| US-20170319611-A1 | METHODS AND COMPOSITIONS COMPRISING AKT INHIBITORS AND/OR PHOSPHOLIPASE D INHIBITORS | PLD1, PLD2, PIK3CD | GRIN1 3083/4885GRIN2A 3663/4885GRIN2D 2147/4885 |
| US-20060198884-A1 | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane | ADORA1, ADORA2A, SARAF | GRIN1 58/4885GRIN2A 17/4885GRIN2D 8/4885 |
| US-20050014743-A1 | Combination of an NMDA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders | GRIN2A, GRIN2B, GRIN3B | GRIN1 5/4885GRIN2A 1/4885GRIN2D 10/4885 |
| US-20070270500-A1 | Compositions Comprising Cyclohexylamines and Aminoadamantanes | AAAS, SI, ACMSD | GRIN1 4139/4885GRIN2A 3295/4885GRIN2D 3759/4885 |
| US-20090081259-A1 | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect | NMBR, NMUR1, CNR1 | GRIN1 207/4885GRIN2A 134/4885GRIN2D 438/4885 |
| US-20120046302-A1 | METHODS OF TREATING CNS DISORDERS | GRIN3A, GRIN2A, GRIN2B | GRIN1 8/4885GRIN2A 2/4885GRIN2D 14/4885 |
| US-20050288375-A1 | Method and composition for treating neurodegenerative disorders | GRIN2A, GRIN2B, GRIN3A | GRIN1 5/4885GRIN2A 1/4885GRIN2D 4/4885 |
| US-20060205822-A1 | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect | NMBR, NMUR1, CNR1 | GRIN1 207/4885GRIN2A 134/4885GRIN2D 438/4885 |
| US-20110236439-A1 | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane | ADORA1, ADORA2A, SARAF | GRIN1 58/4885GRIN2A 17/4885GRIN2D 8/4885 |
| US-20040087658-A1 | Synergistic mixture; Alzheimer's disease therapy | ACHE, BACE1, CHRNA5 | GRIN1 24/4885GRIN2A 29/4885GRIN2D 94/4885 |
| US-20150025041-A1 | ANTIVIRAL THERAPIES WITH PHOSPHOLIPASE D INHIBITORS | PLD1, PLA2G2D, PLD2 | GRIN1 3309/4885GRIN2A 3415/4885GRIN2D 2221/4885 |
| US-20140350114-A1 | COMPOSITIONS COMPRISING CYCLOHEXYLAMINES AND AMINOADAMANTANES | AAAS, SI, ACMSD | GRIN1 4139/4885GRIN2A 3295/4885GRIN2D 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.